[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344729-105":59,"doc-detail-344729-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","translational-evaluation-of-bub1b-as-a-precision-medicine-biomarker-for-hepatocellular-carcinoma","Translational evaluation of BUB1B as a precision medicine biomarker for hepatocellular carcinoma","","Hepatocellular carcinoma (HCC) accounts for most primary liver cancers and is marked by late diagnosis and poor outcomes due to limited early-detection and personalization biomarkers. This study translationally evaluates BUB1B, a spindle assembly checkpoint component, as a precision medicine biomarker using integrative multi-omics analysis and clinical validation. Pan-cancer analysis shows BUB1B upregulation, and high levels predict worse survival and correlate with clinicopathologic and genomic instability features. Immune profiling suggests immune escape, while drug sensitivity and inhibitor studies indicate actionable MAPK pathway regulation and improved therapeutic stratification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/translational-evaluation-of-bub1b-as-a-precision-medicine-biomarker-for-hepatocellular-carcinoma/344729/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/translational-evaluation-of-bub1b-as-a-precision-medicine-biomarker-for-hepatocellular-carcinoma/344729.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is BUB1B and why is it evaluated in hepatocellular carcinoma?","Question",{"text":112,"@type":113},"BUB1B is a spindle assembly checkpoint component linked to mitotic control and chromosomal stability. The study evaluates whether it can function as a precision medicine biomarker for HCC progression, prognosis, and therapeutic guidance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does BUB1B expression relate to patient outcomes in this study?",{"text":117,"@type":113},"High BUB1B expression independently predicts poor overall survival and correlates with tumor size, BCLC stage, Ki-67 index, and AFP levels, indicating worse clinical behavior.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic implications does the study suggest from BUB1B findings?",{"text":121,"@type":113},"The work identifies high BUB1B expression as predictive of increased sensitivity to sorafenib, paclitaxel, and doxorubicin. Mechanistic experiments with selective BUB1B inhibitors show MAPK pathway regulation, supporting BUB1B as an actionable target for risk stratification and precision therapeutics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344729,1790786075,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nTranslational evaluation of BUB1Bas a precision medicine biomarker for hepatocellular carcinoma  \nChun-yu Sun1,4, Xi Yu1,4, Lin-qi Deng2,4, Yu-jia Han1, Li-jie He1􀀍 & Hong-yan Yan3􀀍  \nHepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers, characterized by late-stage diagnosis and poor prognosis due to insufficient biomarkers for early detection and personalized therapy. This study comprehensively investigated BUB1B, a spindle assembly checkpoint component, as a precision medicine biomarker in HCC through integrative multi-omics analysis and clinical validation. Pan-cancer analysis using The Cancer Genome Atlas (TCGA) revealed significant BUB1B upregulation across 19 tumor types, with robust overexpression in HCC (P \u003C 0.05) . High BUB1B expression independently predicted poor overall survival (hazard ratio = 1.39, 95% confidence interval:  \n1.20–1.63, P \u003C 0.001) and correlated with tumor size, Barcelona Clinic Liver Cancer (BCLC) stage, Ki- 67 index, and alpha-fetoprotein (AFP) levels. BUB1B expression strongly associated with genomic instability markers including homologous recombination deficiency and microsatellite instability (all P \u003C 0.001). Immune profiling revealed paradoxical enrichment of activated T cells yet elevated Tumor Immune Dysfunction and Exclusion (TIDE) scores (P \u003C 0.001), suggesting immune escape and potential resistance to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors.  \nDrug sensitivity analysis identified high BUB1B expression as predictive of enhanced sensitivity to sorafenib, paclitaxel, and doxorubicin. Clinical validation in an independent cohort confirmed BUB1Boverexpression, cytoplasmic localization, and association with worse survival (P = 0.044) . Mechanistic studies using selective BUB1B inhibitors demonstrated comprehensive mitogen-activated protein kinase (MAPK) pathway regulation, with significant suppression of HRAS (60% reduction), extracellular signal-regulated kinase 1/2 (ERK1/2) (40–60% reduction), and p38 isoforms (30–60% reduction) (all P \u003C 0.05).These findings establish BUB1B as a clinically actionable biomarker for risk stratification and precision therapeutics in HCC management.  \nKeywords Hepatocellular carcinoma, BUB1B, Biomarker, Immune infiltration, Drug sensitivity, Prognosis  \nAbbreviations  \nHCC Hepatocellular Carcinoma IHC Immunohistochemistry MSI Microsatellite Instability  \nTCGA The Cancer Genome Atlas GEO Gene expression omnibus LIHC Liver hepatocellular carcinoma  \nOSO Overall Survival  \nHRD Homologous recombination deficiency TIDE Tumor immune dysfunction and exclusio HBV Hepatitis B Virus  \nHPA Human protein atlas DFI Disease-free interval  \nDSS Disease-specific survival PFI Progression-free interval  \n1Oncology department, People’s Hospital of Liaoning Province, China Medical University, Shenyang, China.  \n2Psychiatry Department, The Mental Health Center of Liaoning Province, Tieling, China. 3Oncology department, Dandong Central Hospital, China Medical University, Dandong, China. 4These authors contributed equally: Chun-yu Sun, Xi Yu and Lin-qi Deng. 􀀍 email: [hlj88896@163.com](hlj88896@163.com); [13604953651@163.com](13604953651@163.com)  \nHepatocellular carcinoma (HCC), constituting almost 90% of all primary liver malignancies, is a tumor derived from hepatocytes and characterized by high incidence and mortality1. Early-stage HCC is frequently asymptomatic, and currently used biomarkers exhibit inadequate accuracy for early detection, leading to diagnosis at advanced stages in many patients2,3. HCC displays marked heterogeneity and aggressiveness, progresses rapidly, and tends to recur, resulting in limited therapeutic effectiveness and poor prognosis in latestage disease4,5. The absence of routine molecular classification markers further hampers the development of targeted and personalised therapies6. Comprehensive analysis of gene","cbCaijdEGwMpkxRj","https://ap.wps.com/l/cbCaijdEGwMpkxRj","pdf",5293707,15,"English","# Translational evaluation framework\n## Pan-cancer and TCGA evidence for BUB1B\n## Prognostic and clinicopathologic correlations\n## Genomic instability and immune profiling\n## Drug sensitivity predictions and clinical validation\n## Mechanistic pathway regulation via BUB1B inhibitors","[{\"question\":\"What is BUB1B and why is it evaluated in hepatocellular carcinoma?\",\"answer\":\"BUB1B is a spindle assembly checkpoint component linked to mitotic control and chromosomal stability. The study evaluates whether it can function as a precision medicine biomarker for HCC progression, prognosis, and therapeutic guidance.\"},{\"question\":\"How does BUB1B expression relate to patient outcomes in this study?\",\"answer\":\"High BUB1B expression independently predicts poor overall survival and correlates with tumor size, BCLC stage, Ki-67 index, and AFP levels, indicating worse clinical behavior.\"},{\"question\":\"What therapeutic implications does the study suggest from BUB1B findings?\",\"answer\":\"The work identifies high BUB1B expression as predictive of increased sensitivity to sorafenib, paclitaxel, and doxorubicin. Mechanistic experiments with selective BUB1B inhibitors show MAPK pathway regulation, supporting BUB1B as an actionable target for risk stratification and precision therapeutics.\"}]","Translational evaluation of BUB1B as a precision medicine biomarker for hepatocellular carcinoma | PDF",1790055087,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d1286898183ff5c4b7ae84a05ef682e.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ee8a28ea346f64a9250a5cafb221c1b.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/420a73dd3c5b86e26567f0bbdef15f2f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f511c4a0910ad5b7b2e11ee03299f46.webp",980,1287]